Assessment of fibrosis in chronic liver diseases

Journal of Digestive Diseases

Volumn 10, Issue 1, 2009, Pages 7-14

  Zhou, Kun ^a   Lu, Lun Gen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Liver biopsy; Liver fibrosis; Non invasive test; Serum marker panel; Transient elastography

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINO TERMINAL TELOPEPTIDE; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; COLLAGEN TYPE 4; COLLAGENASE; COLLAGENASE INHIBITOR; FIBRONECTIN; GAMMA GLUTAMYLTRANSFERASE; GLYCOPROTEIN GP 39; HAPTOGLOBIN; HYALURONIC ACID; LAMININ; LYMPHOTOXIN; MANGANESE SUPEROXIDE DISMUTASE; MATRIX METALLOPROTEINASE; N ACETYL BETA GLUCOSAMINIDASE; PLATELET DERIVED GROWTH FACTOR; PROTHROMBIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL;

ABDOMINAL RADIOGRAPHY; ARTICLE; BLOOD ANALYSIS; BODY MASS; CHRONIC LIVER DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIFFUSION WEIGHTED IMAGING; DIGITAL IMAGING; DOPPLER ECHOGRAPHY; ECHOGRAPHY; ELASTOGRAPHY; FOLLOW UP; GOLD STANDARD; HEPATIC VEIN; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBSERVER VARIATION; PRESSURE GRADIENT; PRIORITY JOURNAL; PROTHROMBIN TIME; SAMPLING ERROR; SENSITIVITY AND SPECIFICITY; SEROLOGY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; THROMBOCYTE COUNT; VENOUS PRESSURE;

BIOLOGICAL MARKERS; BIOPSY, NEEDLE; BLOOD FLOW VELOCITY; DIFFUSION MAGNETIC RESONANCE IMAGING; HEPATITIS, CHRONIC; HUMANS; LIVER CIRRHOSIS; SEROLOGIC TESTS;

EID: 60349096383     PISSN: 17512972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2008.00356.x     Document Type: Article

References (53)

1. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
2. McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990; 99: 1396-400.
3. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: The smaller the sample, the milder the disease. J Hepatol 2003; 39: 239-44.
4. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond. Hepatology 2000; 31: 241-6.
5. Goodman ZD, Becker RL Jr, Pockros PJ, Afdhal NH. Progression of fibrosis in advanced chronic hepatitis C: Evaluation by morphometric image analysis. Hepatology 2007; 45: 886-94.
6. Dioguardi N, Franceschini B, Aletti G, Russo C, Grizzi F. Fractal dimension rectified meter for quantification of liver fibrosis and other irregular microscopic objects. Anal Quant Cytol Histol 2003; 25: 312-20.
7. Asselah T, Bieche I, Laurendeau I et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 2005; 129: 2064-75.
8. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: A critical appraisal. Hepatology 2003; 37: 493-503.
9. Burroughs AK, Groszmann R, Bosch J et al. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: Is hepatic venous pressure gradient a better end point? Gut 2002; 50: 425-7.
10. Afdhal NH, Nunes D. Evaluation of liver fibrosis: A concise review. Am J Gastroenterol 2004; 99: 1160-74.
11. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001; 357: 1069-75.
12. Kaul V, Friedenberg FK, Braitman LE et.al. Development and validation of a model to diagnose cirrhosis in patients with hepatitis C. Am J Gastroenterol 2002; 97: 2623-8.
13. Forns X, Ampurdanes S, Llovet JM et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.
14. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38, 518-26.
15. Rosenberg WM, Voelker M, Thiel R et al. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 2004; 127: 1704-13.
16. Patel K, Gordon SC, Jacobson I et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004; 41: 935-42.
17. Sud A, Hui JM, Farrell GC et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004; 39: 1239-47.
18. Leroy V, Monier F, Bottari S et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004; 99: 271-9.
19. Lok AS, Ghany MG, Goodman ZD et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT-C cohort. Hepatology 2005; 42: 282-92.
20. Adams LA, Bulsara M, Rossi E et al. Hepascore: An accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-73.
21. Cales P, Oberti F, Michalak S et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42: 1373-81.
22. Kelleher TB, Mehta SH, Bhaskar R et.al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index. J Hepatol 2005; 43: 78-84.
23. Sakugawa H, Nakayoshi T, Kobashigawa K et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005; 11: 255-9.
24. Hui AY, Chan HL, Wong VW et.al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 2005; 100: 616-23.
25. Zeng MD, Lu LG, Mao YM et.al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005; 42: 1437-45.
26. Sterling RK, Lissen E, Clumeck N et.al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/ HCV coinfection. Hepatology 2006; 43: 1317-25.
27. Fontana RJ, Kleiner DE, Bilonick R et al. Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology 2006; 44: 925-35.
28. Mohamadnejad M, Montazeri G, Fazlollahi A et.al. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol 2006; 101: 2537-45.
29. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007; 45: 297-306.
30. Alsatie M, Kwo PY, Gingerich JR et.al. A multivariable model of clinical variables predicts advanced fibrosis in chronic hepatitis C. J Clin Gastroenterol 2007; 41: 416-21.
31. Esmat G, Metwally M, Zalata KR et al. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol 2007; 46: 620-7.
32. Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54.
33. Bourliere M, Penaranda G, Renou C et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: Proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006; 13: 659-70.
34. Leroy V, Hilleret MN, Sturm N et.al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 775-82.
35. Poynard T, Zoulim F, Ratziu V et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005; 100: 1970-80.
36. Poon TC, Hui AY, Chan HL et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: A pilot study. Clin Chem 2005; 51: 328-35.
37. Morra R, Munteanu M, Bedossa P et al. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007; 26: 847-58.
38. Kam RK, Poon TC, Chan HL, Wong N, Hui AY, Sung JJ. High-throughput quantitative profiling of serum N-glycome by MALDI-TOF mass spectrometry and N-glycomic fingerprint of liver fibrosis. Clin Chem 2007; 53: 1254-63.
39. Lim AK, Taylor-Robinson SD, Patel N et al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 2005; 54: 128-33.
40. Colagrande S, Centi N, La Villa G, Villari N. Transient hepatic attenuation differences. AJR Am J Roentgenol 2004; 183: 459-64.
41. Ziol M, Handra-Luca A, Kettaneh A et.al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.
42. Colletta C, Smirne C, Fabris C et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005; 42: 838-45.
43. Fraquelli M, Rigamonti C, Casazza G et.al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-73.
44. Castera L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
45. Foucher J, Chanteloup E, Vergniol J et al. Diagnosis of cirrhosis by transient elastography (FibroScan): A prospective study. Gut 2006; 55: 403-8.
46. Friedrich-Rust M, Ong MF, Herrmann E et al. Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol 2007; 188: 758-64.
47. Yin M, Talwalkar JA, Glaser KJ et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007;5: 1207-13 e2.
48. Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB. Liver fibrosis: Noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology 2006; 239: 425-37.
49. Lewin M, Poujol-Robert A, Boelle PY et.al. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 2007; 46: 658-65.
50. Chappell KE, Patel N, Gatehouse PD et.al. Magnetic resonance imaging of the liver with ultrashort TE (UTE) pulse sequences. J Magn Reson Imaging 2003; 18: 709-13.
51. Lim AK, Patel N, Hamilton G, Hajnal JV, Goldin RD, Taylor-Robinson SD. The relationship of in vivo 31P MR spectroscopy to histology in chronic hepatitis C. Hepatology 2003; 37: 788-94.
52. Poynard T, Munteanu M, Imbert-Bismut F et.al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50: 1344-55.
53. Matalka II, Al-Jarrah OM, Manasrah TM. Quantitative assessment of liver fibrosis: A novel automated image analysis method. Liver Int 2006; 26: 1054-64.